Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation
- Discussing how site specific ConjuAll platform enables discrete DAR ADCs with circulation stable bioconjugation
- Leveraging proprietary beta glucuronidase technology to enable unprecedented preclinical therapeutic indexes through tumor selective release and payload activation
- Assessing early clinical safety and efficacy across payload classes to validate the LCB platform